Literature DB >> 15034658

[Neurological complications of infective endocarditis].

K Angstwurm1, A C Borges, E Halle, E Schielke, J R Weber.   

Abstract

Infective endocarditis involves the brain in 20-40% of cases. The neurologic syndrome often is the presenting feature. The most frequent neurologic complication is cerebral ischemia. In these patients and those with intracranial hemorrhage, a heart murmur as well as systemic signs of inflammation point to endocarditis. The encephalopathy in endocarditis is mostly due to cerebral infarction. In bacterial meningitis and brain abscess an uncommon isolate arouses suspicion. The most important therapy is antibiotic treatment. Valve replacement improves outcome; in the acute phase of endocarditis, however, it is only necessary in a third of the patients. Neurologic complications interfere with the timing of the valve replacement. If it is urgently required, its risk is reasonable within 3 days after cerebral ischemia; if possible 2-4 weeks should be waited. Cases of successful valve replacement within 4 weeks after intracranial hemorrhage have been reported, but it is recommended to postpone it for 4-6 weeks. There are no data available for the other neurologic complications. Even today patients with endocarditis challenge the diagnostic and therapeutic capacity of various disciplines.

Entities:  

Mesh:

Year:  2004        PMID: 15034658     DOI: 10.1007/s00115-004-1685-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  47 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Vegetations in endocarditis: big is bad, but is there more to it?

Authors:  Christopher H Cabell; Vance G Fowler
Journal:  Am Heart J       Date:  2003-08       Impact factor: 4.749

3.  The risk of stroke and death in patients with aortic and mitral valve endocarditis.

Authors:  C H Cabell; K K Pond; G E Peterson; D T Durack; G R Corey; D J Anderson; T Ryan; A S Lukes; D J Sexton
Journal:  Am Heart J       Date:  2001-07       Impact factor: 4.749

4.  The presence of infection-related antiphospholipid antibodies in infective endocarditis determines a major risk factor for embolic events.

Authors:  L I Kupferwasser; G Hafner; S Mohr-Kahaly; R Erbel; J Meyer; H Darius
Journal:  J Am Coll Cardiol       Date:  1999-04       Impact factor: 24.094

5.  Infective endocarditis due to Staphylococcus aureus: deleterious effect of anticoagulant therapy.

Authors:  P Tornos; B Almirante; S Mirabet; G Permanyer; A Pahissa; J Soler-Soler
Journal:  Arch Intern Med       Date:  1999-03-08

6.  Current multimodality management of infectious intracranial aneurysms.

Authors:  J Y Chun; W Smith; V V Halbach; R T Higashida; C B Wilson; M T Lawton
Journal:  Neurosurgery       Date:  2001-06       Impact factor: 4.654

7.  Prosthetic valve endocarditis 1976-1987. Antibiotics, anticoagulation, and stroke.

Authors:  J Davenport; R G Hart
Journal:  Stroke       Date:  1990-07       Impact factor: 7.914

8.  Mycotic aneurysm, subarachnoid hemorrhage, and indications for cerebral angiography in infective endocarditis.

Authors:  A V Salgado; A J Furlan; T F Keys
Journal:  Stroke       Date:  1987 Nov-Dec       Impact factor: 7.914

9.  Hemorrhagic transformation in cardioembolic cerebral infarction.

Authors:  C R Hornig; T Bauer; C Simon; S Trittmacher; W Dorndorf
Journal:  Stroke       Date:  1993-03       Impact factor: 7.914

10.  Negative predictive value of the Duke criteria for infective endocarditis.

Authors:  G A Dodds; D J Sexton; D T Durack; T M Bashore; G R Corey; J Kisslo
Journal:  Am J Cardiol       Date:  1996-02-15       Impact factor: 2.778

View more
  1 in total

1.  Pathophysiology and treatment of bacterial meningitis.

Authors:  Olaf Hoffman; R Joerg Weber
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.